MarginsXMarginsX
Home › Markets › Health Care › TVTX

Travere Therapeutics Inc. (TVTX)

TVTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$49.70
-1.88% on the day
Market cap
$4.8B
Mid cap
Revenue · 2025
$490.7M
+110.5% on 2024
Net income · 2025
-$25.5M
-5.2% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/0001438533-26-000014-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTVTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001438533
SEC industry codePharmaceutical Preparations
Incorporated inCA

Financials · 2025

LineValue
Revenue$490.7M
Net income-$25.5M
Operating income-$62.8M
Net margin-5.2%
Operating margin-12.8%
Revenue growth+110.5%
Cash$93.0M
Total assets$605.2M
P/E (computed)Net income was not positive
P/S (computed)9.7×

Warning signs

Cash runway
Cash-flow positive
$123.5M cash at September 30, 2026
Share count, 1 year
+7.3%
2025-10-27 to 2026-10-28 · +27.7% over 3 years
Going-concern doubt
No
10-Q filed November 2, 2026
Insider net buying, 12 months
-$102.5M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-02
Cash and burn$123.5M cash; operating cash flow $44.1M a quarter.Report 2026-09-30
Shares outstanding95,992,155 (2026-10-28); 89,472,327 a year earlier; 75,145,831 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-05-07
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-03-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $102.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$224.6M-$52.3M$98.2M$123.5MNo debt tags$651.0M10-Q 2026-11-02
Q2 2026
2026-06-30
$169.6M-$34.8M$58.1M$117.7MNo debt tags$591.3M10-Q 2026-08-04
Q1 2026
2026-03-31
$127.2M-$37.1M-$40.4M$78.4MNo debt tags$536.2M10-Q 2026-05-04
Q4 2025
2025-12-31
$129.7M$2.7M$60.7M$93.0M$311.7M$490.7M10-K 2026-02-19
Q3 2025
2025-09-30
$164.9M$25.7M$14.3M$110.9M$311.4M$435.8M10-Q 2026-11-02
Q2 2025
2025-06-30
$114.4M-$12.8M$5.0M$75.2M$379.9M$333.9M10-Q 2026-08-04
Q1 2025
2025-03-31
$81.7M-$41.2M-$42.2M$61.9M$379.4M$273.5M10-Q 2026-05-04
Q4 2024
2024-12-31
$74.8M-$60.3M-$35.7M$58.5M$379.0M$233.2M10-K 2026-02-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-05-07
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-11-02
Latest current report8-K2026-11-02
Latest proxyDEFA14A2026-04-06

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.1%
1 month-2.2%
3 months-17.5%
Year to date+32.6%
1 year+49.5%
From 52-week high-25.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
COGTCogent Biosciences Inc.$27.44-3.92%$4.8B
EWTXEdgewise Therapeutics Inc.$43.68-4.90%$4.8B
IONSIonis Pharmaceuticals Inc.$28.01-3.61%$4.7B
DNTHDianthus Therapeutics Inc.$89.55-2.46%$5.0B
LQDALiquidia Corporation$56.37-1.81%$5.1B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B
ERASErasca Inc.$15.11-3.51%$5.3B
MANEVeradermics Incorporated$128.05-1.24%$5.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier